Target in focus: $400 per share, roughly 50% above ALNY's recent trading range near $265 and closely aligned with the analyst consensus of about $394–$412. Strongest bullish factor: Rapid uptake of AMVUTTRA in transthyretin amyloidosis cardiomyopathy (ATTR-CM), with the TTR franchise exceeding $1 billion in quarterly revenue.

L3Harris Technologies (LHX) shares closed near $256, down roughly 10.5% over the past 30 days and near the low end of a 52-week range of $256.05 to $379.23. A leadership crisis—the ouster of Chairman and CEO Christopher Kubasik over conduct violations—was the primary near-term catalyst for the selloff.

MasTec (MTZ) shares declined about 11% over the last 30 days, ending near $237 from roughly $267 a month earlier. The slide followed a second-quarter 2026 earnings report that beat on revenue but disappointed investors on forward guidance.

ChargePoint (CHPT) shares climbed roughly 59% over the last 30 days, from about $6.22 in early August to $9.89 by September 4, 2026. The advance was concentrated in a single catalyst: a stronger-than-expected fiscal second-quarter earnings report released September 2, 2026.

Photronics trades near $29, making the $40 level a roughly 37% move higher — a meaningful but not extreme distance. The $40 target aligns closely with Wall Street's consensus 12-month price target, which sits in the low-to-mid $40s.

Robinhood (HOOD) shares climbed roughly 31% over the last 30 days, rising from about $93 to a closing price of $122.11 on September 4, 2026. The advance was fueled by a broad cryptocurrency rally, with Bitcoin topping $77,000 and then $80,000, alongside renewed optimism over U.S. crypto regulation.

American Airlines Group (AAL) fell roughly 20.8% over the past 30 days, from about $16.58 to $13.13 per share. The decline was driven primarily by a sharp rise in jet fuel costs tied to Middle East tensions and by management's repeated cuts to earnings and capacity guidance.

Investors are watching whether Navitas Semiconductor (NVTS) can climb back toward the $20 level , roughly 54% above its recent price near $13. The strongest bullish case rests on rapidly growing demand for gallium nitride (GaN) and silicon carbide (SiC) power chips in AI data centers.

Turning Point Brands recently traded near $75, placing the $100 target roughly 33% above current levels — a meaningful but not unrealistic gap. The $100 mark is a natural psychological milestone, and TPB traded well above it as recently as early 2026, peaking near $147 in February.

Bilibili's American depositary shares fell roughly 18% over the trailing 30 days, closing at $15.23 on September 4, 2026, versus $18.58 on August 5, 2026. The slide accelerated after Bilibili announced a $700 million convertible notes offering alongside a concurrent Tencent share placement, raising dilution and share-overhang concerns.

YUMC traded near $43.60 in early September 2026, down roughly 8% over the trailing 30 days and within a 52-week range of roughly $40.15 to $58.39. Second-quarter 2026 results topped expectations, with EPS of $0.70 versus a $0.67 consensus and revenue of $3.14 billion, up about 13% year over year.

Selected price target: $9, matching the Wall Street consensus analyst price target, versus a recent share price near $3. Strongest bullish factor: Positive clinical data for lead drug candidate tegoprubart in kidney and islet cell transplantation, with a Phase 3 kidney transplant program now in planning.

The central question is whether Immunic can climb from roughly $13 to a $20 price target, a psychological round-number milestone that sits just below the low end of most Wall Street targets. The strongest bullish catalyst is the Phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis (MS), with top-line data expected by the end of 2026.

YETI Holdings shares fell roughly 22% over the past 30 days, sliding from about $52.51 to near $40.82, largely after its second-quarter 2026 earnings report. The selloff followed an earnings-per-share beat that investors viewed as inflated by a one-time tariff refund, while adjusted operating income actually declined 7%.

Denali Therapeutics shares closed near $22.28 , leaving a $30 price target roughly 35% above the latest close. Wall Street remains broadly constructive, with an average analyst price target near $35 and individual targets ranging from about $27 to $42.

L3Harris Technologies (LHX) shares fell roughly 10.4% over the trailing 30 days, ending near $256 and touching a fresh 52-week low. The decline accelerated after an abrupt leadership transition, as Chairman and CEO Chris Kubasik was replaced following a code-of-conduct investigation.

The $5 level sits roughly 60% above ioneer's recent price near $3.14 and represents a round-number recovery target the stock traded close to in late 2025. A December 2025 analyst survey placed the average 12-month price target near $5.10 , with individual estimates clustered just above $5.

MLTX shares declined roughly 14.5% over the trailing 30 days, from $17.55 on August 5, 2026, to $15.01 on September 4, 2026. The pullback followed positive Phase 3 IZAR-1 topline data for sonelokimab in psoriatic arthritis, as investors sold the news amid the absence of placebo-comparison figures.

The selected price target is $30 per share , roughly 67% above the most recent closing price near $17.92. The strongest bullish factors are improving revenue, low valuation multiples, and fixed-fee contracts with three major U.S. airlines.

The widely discussed $10 price target reflects the Wall Street consensus, with analyst 12-month targets ranging from $8.75 to $12.00. Reaching $10 from the recent level near $3.41 would require roughly 190% upside — a move that depends on a sustained fundamental turnaround.